A new gene risk score, informed by machine learning, can predict weight-loss outcomes after Roux-en-Y gastric bypass surgery.

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

It’s been a month since Kári Stefánsson, the founder and former chief executive of the pioneering Icelandic genomics company ...

Today, Benzinga's options scanner spotted 13 options trades for Amgen. This is not a typical pattern. The sentiment among ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...